ULB - Free University of Brussels
Région de Bruxelles-Capitale/Brussels Hoofdstedelijk Gewest (BE1) · Belgium
ERC Consolidator Grant · 2019
Disentangling the stringent response to engineer novel anti-persister drugs
Bacterial “superbugs”, refringent to antibiotic treatments, have rapidly increased with the turn of the century. Slow growing, dormant cells (known as persisters) are subpopulations of bacteria that tolerate antibiotics and are considered a primary source of infections for antibiotic-resistant pathogens since they are difficult to eradicate in conventional ways. Mutations in RelA/SpoT (RSH), the effectors of the stringent response, promote antibiotic tolerance and persistent infections and are commonly selected in clinical settings of a variety of pathogens. However, despite the importance of the RSH-mediated stringent response, there is no comprehensive knowledge on the inner workings of…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.